Actively Recruiting

Phase 2
Age: 65Years +
All Genders
NCT07390552

A Study of PLH-2301 in Subjects With Sarcopenia

Led by Pluto Inc. · Updated on 2026-05-12

168

Participants Needed

5

Research Sites

59 weeks

Total Duration

On this page

Sponsors

P

Pluto Inc.

Lead Sponsor

S

Symyoo

Collaborating Sponsor

AI-Summary

What this Trial Is About

This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of PLH-2301 in subjects with sarcopenia. Eligible subjects aged 65 years and older will be randomized to receive placebo or one of three dose levels of PLH-2301 once daily for 12 weeks. The primary objective is to assess the effect of PLH-2301 on physical function compared with placebo.

CONDITIONS

Official Title

A Study of PLH-2301 in Subjects With Sarcopenia

Who Can Participate

Age: 65Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female subjects aged 65 years or older at the time of consent
  • Diagnosis of sarcopenia based on predefined diagnostic criteria
  • Short Physical Performance Battery (SPPB) total score within the protocol-defined range at screening
  • Stable body weight for at least 3 months prior to screening
  • Able to walk independently with or without assistive devices
  • Willing and able to comply with study procedures
  • Provided written informed consent prior to any study-specific procedures
Not Eligible

You will not qualify if you...

  • History of clinically significant neuromuscular or musculoskeletal disorders that could affect muscle function
  • Uncontrolled cardiovascular, hepatic, renal, or metabolic disease
  • Use of medications known to affect muscle mass or function within the protocol-defined washout period
  • Participation in another interventional clinical trial within 3 months prior to screening
  • Any medical or psychiatric condition that, in the investigator's opinion, would interfere with study participation

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, South Korea

Actively Recruiting

2

The Catholic University of Korea, St. Vincent's Hospital

Suwon, Gyeonggi-do, South Korea

Actively Recruiting

3

Korea University Anam Hospital

Seoul, Seoul, South Korea, 02841

Actively Recruiting

4

Seoul St. Mary's Hospital

Seoul, Seoul, South Korea, 06591

Actively Recruiting

5

Korea University Guro Hospital

Seoul, Seoul, South Korea, 08308

Actively Recruiting

Loading map...

Research Team

C

CRO PM

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study of PLH-2301 in Subjects With Sarcopenia | DecenTrialz